Strides Pharma Science’s arm receives EIR from USFDA

18 Jan 2023 Evaluate

Strides Pharma Science’s biologics arm -- Stelis Biopharma has received Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) specific to Drug-Device Combination Products to be commercialized at Stelis’ flagship facility in Bengaluru, India.

This Abbreviated Quality System Inspection Technique (QSIT) drug preapproval on-site inspection was specifically conducted by the USFDA for the drug-device combination products that are to be manufactured/ commercialized at the site for the partner products by Stelis. Previously, the USFDA issued an EIR to Stelis in September 2022 based on on-site Pre-Approval Inspection (PAI) and, consequently, the first product approval for one of its key customers in December 2022.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

815.00 -45.30 (-5.27%)
21-Jan-2026 10:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.65
Dr. Reddys Lab 1152.40
Cipla 1368.60
Zydus Lifesciences 871.65
Lupin 2161.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×